PhaseBio Pharmaceuticals, Inc. (2K4.F)

0,0690 0,0000 (0,00%) Börsenschluss: 10:16AM CEST

PhaseBio Pharmaceuticals, Inc.

1 Great Valley Parkway
Suite 30
Malvern, PA 19355
United States
610 981 6500
https://phasebio.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 60

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jonathan P. Mow MBA	President, CEO & Director	834,5k	N/A	1965
Mr. Lawrence R. Perkins	Chief Restructuring Officer & Principal Financial Officer	N/A	N/A	1977
Ms. Susan Elizabeth Arnold Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	1975
Mr. Kristopher L. Hanson	SVP, General Counsel & Corporate Secretary	N/A	N/A	1972
Mr. Glen G. Burkhardt	Senior Vice President of Human Resources	N/A	N/A	1959
Mr. Jonathan J. Birchall	Chief Commercial Officer	N/A	N/A	1969

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

PhaseBio Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.